BioWorld

Sep. 29, 2003

View Archived Issues

Novogen Cancer Subsidiary Files IPO, Seeks Up To $13M

Chromosome 15's 4 Mutant Genes Focus Hotspots For Derangements In Michigan, Penn Research Centers

Hollis-Eden Raises $62.5M; This Time In Public Offering

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Appointments And Advancements

Other News To Note

After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work

Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 4, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...